Literature DB >> 11438632

Improved prediction of therapeutic absorbed doses of radioiodine in the treatment of thyroid carcinoma.

J Hermanská1, M Kárný, J Zimák, L Jirsa, M Sámal, P Vlcek.   

Abstract

UNLABELLED: We proposed an alternative to a monoexponential model of radioiodine kinetics to obtain a more accurate estimate of absorbed doses to postsurgical thyroid remnants. We suggested that part of the difference between the predicted and the actually absorbed therapeutic doses of (131)I, usually explained by radiation damage of thyroid cells, can be attributed to errors resulting from inadequate sampling of data and oversimplified modeling.
METHODS: A standard monoexponential model and alternative biphasic model (incorporating both radioiodine uptake and clearance) were used on 2 sets of patient data to fit time-activity measurements after administration of diagnostic and therapeutic activities of radioiodine. One set of data consisted of 633 records of routine measurements, and the second set consisted of 71 prospectively collected records with measurements performed more frequently and for a longer time. The time-activity curves derived from the 2 models were used to calculate residence times for diagnostic and therapeutic activities of (131)I, and the respective residence times were compared using the paired t test. Errors of fitting and prediction of therapeutic time-activity data were also calculated.
RESULTS: With both models, a statistically significant difference (P < 0.01) was found between residence times after diagnostic administration of (131)I and residence times after therapeutic administration of (131)I. However, the effects of biphasic modeling and of improved sampling substantially reduced the difference (P < 0.01). Errors of fitting and prediction were smaller with the biphasic model than with the monoexponential model (P < 0.01).
CONCLUSION: The biphasic model more accurately predicts (131)I kinetics when applied to measurements in the short interval after diagnostic administration of radioiodine. The minimum requirement for the biphasic model is measurement twice a day at intervals > 6 h for at least 3 d after administration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438632

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

1.  Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape.

Authors:  Joseph J Grudzinski; Ronald R Burnette; Jamey P Weichert; Robert Jeraj
Journal:  Cancer Biother Radiopharm       Date:  2010-08       Impact factor: 3.099

2.  A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.

Authors:  Glenn D Flux; Masud Haq; Sarah J Chittenden; Susan Buckley; Cecilia Hindorf; Kate Newbold; Clive L Harmer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-04       Impact factor: 9.236

3.  Cherenkov light emission in molecular radiation therapy of the thyroid and its application to dosimetry.

Authors:  Jigar Dubal; Pedro Arce; Christopher South; Lucia Florescu
Journal:  Biomed Opt Express       Date:  2022-03-23       Impact factor: 3.562

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.